Anergis
Developing novel allergy vaccines targeting the most common allergies
Epalinges, Switzerlandanergis.ch ↗
Total raised
€36M
€36,418,181
Funding rounds
3
Investors
3
distinct backers
Active since
2011-02
latest 2016-03
Funding by year
EUR raised per yearSignals
Medium confidenceRaise-next likelihood17
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
Exit likelihood19
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
- ▲ €30M+ raised
- ▲ 15y since founding
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-04-01 | Series C | €4.6M | — | View deal → |
| 2014-12-01 | Series B | €14M | — | View deal → |
| 2011-03-01 | Series A | €18M | BioMed Partners,Sunstone Capital,Vinci Capital | View deal → |
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy